CO6230993A2 - Uso de una sal de cobre enmascarada o recubierta para el tratamiento de degeneracion macular - Google Patents
Uso de una sal de cobre enmascarada o recubierta para el tratamiento de degeneracion macularInfo
- Publication number
- CO6230993A2 CO6230993A2 CO09103873A CO09103873A CO6230993A2 CO 6230993 A2 CO6230993 A2 CO 6230993A2 CO 09103873 A CO09103873 A CO 09103873A CO 09103873 A CO09103873 A CO 09103873A CO 6230993 A2 CO6230993 A2 CO 6230993A2
- Authority
- CO
- Colombia
- Prior art keywords
- copper
- copper salt
- coated
- masked
- use according
- Prior art date
Links
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical class [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 title abstract 5
- 208000002780 macular degeneration Diseases 0.000 title abstract 2
- 150000001879 copper Chemical class 0.000 abstract 7
- 239000000463 material Substances 0.000 abstract 7
- 239000002775 capsule Substances 0.000 abstract 5
- 239000011248 coating agent Substances 0.000 abstract 4
- 238000000576 coating method Methods 0.000 abstract 4
- 229910052802 copper Inorganic materials 0.000 abstract 4
- 239000010949 copper Substances 0.000 abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 abstract 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000000873 masking effect Effects 0.000 abstract 2
- 150000003904 phospholipids Chemical class 0.000 abstract 2
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 abstract 2
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 abstract 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 abstract 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical group [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 abstract 1
- QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 abstract 1
- 239000005751 Copper oxide Substances 0.000 abstract 1
- 229920000858 Cyclodextrin Polymers 0.000 abstract 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 108010010803 Gelatin Proteins 0.000 abstract 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 abstract 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 abstract 1
- 229930003268 Vitamin C Natural products 0.000 abstract 1
- 229930003427 Vitamin E Natural products 0.000 abstract 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 abstract 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 abstract 1
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 abstract 1
- -1 but not limited to Chemical class 0.000 abstract 1
- 239000000919 ceramic Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940116318 copper carbonate Drugs 0.000 abstract 1
- 229940079721 copper chloride Drugs 0.000 abstract 1
- 229940108925 copper gluconate Drugs 0.000 abstract 1
- 229910000431 copper oxide Inorganic materials 0.000 abstract 1
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 abstract 1
- GEZOTWYUIKXWOA-UHFFFAOYSA-L copper;carbonate Chemical compound [Cu+2].[O-]C([O-])=O GEZOTWYUIKXWOA-UHFFFAOYSA-L 0.000 abstract 1
- 229960004643 cupric oxide Drugs 0.000 abstract 1
- 238000000354 decomposition reaction Methods 0.000 abstract 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 229920000159 gelatin Polymers 0.000 abstract 1
- 239000008273 gelatin Substances 0.000 abstract 1
- 235000019322 gelatine Nutrition 0.000 abstract 1
- 235000011852 gelatine desserts Nutrition 0.000 abstract 1
- 239000002502 liposome Substances 0.000 abstract 1
- 235000012680 lutein Nutrition 0.000 abstract 1
- 229960005375 lutein Drugs 0.000 abstract 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 abstract 1
- 239000001656 lutein Substances 0.000 abstract 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 abstract 1
- 229940012843 omega-3 fatty acid Drugs 0.000 abstract 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 abstract 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 235000019154 vitamin C Nutrition 0.000 abstract 1
- 239000011718 vitamin C Substances 0.000 abstract 1
- 235000019165 vitamin E Nutrition 0.000 abstract 1
- 229940046009 vitamin E Drugs 0.000 abstract 1
- 239000011709 vitamin E Substances 0.000 abstract 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 abstract 1
- 235000010930 zeaxanthin Nutrition 0.000 abstract 1
- 239000001775 zeaxanthin Substances 0.000 abstract 1
- 229940043269 zeaxanthin Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P20/00—Coating of foodstuffs; Coatings therefor; Making laminated, multi-layered, stuffed or hollow foodstuffs
- A23P20/10—Coating with edible coatings, e.g. with oils or fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/30—Copper compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nanotechnology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Botany (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Obesity (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07104792A EP1974733A1 (en) | 2007-03-23 | 2007-03-23 | Use of a masked or coated copper salt for the treatment of macular degeneration |
| EP07111322 | 2007-06-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6230993A2 true CO6230993A2 (es) | 2010-12-20 |
Family
ID=39477329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO09103873A CO6230993A2 (es) | 2007-03-23 | 2009-09-23 | Uso de una sal de cobre enmascarada o recubierta para el tratamiento de degeneracion macular |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20080233182A1 (OSRAM) |
| EP (1) | EP2124973B1 (OSRAM) |
| JP (1) | JP2010521534A (OSRAM) |
| KR (1) | KR101688656B1 (OSRAM) |
| AR (1) | AR065791A1 (OSRAM) |
| AU (1) | AU2008231847B2 (OSRAM) |
| BR (1) | BRPI0809258B8 (OSRAM) |
| CA (1) | CA2681514C (OSRAM) |
| CL (1) | CL2008000804A1 (OSRAM) |
| CO (1) | CO6230993A2 (OSRAM) |
| DK (1) | DK2124973T3 (OSRAM) |
| EC (1) | ECSP099700A (OSRAM) |
| ES (1) | ES2542694T3 (OSRAM) |
| GT (1) | GT200900251A (OSRAM) |
| IL (1) | IL201109A (OSRAM) |
| MA (1) | MA31293B1 (OSRAM) |
| MX (1) | MX2009010244A (OSRAM) |
| MY (1) | MY164520A (OSRAM) |
| NZ (1) | NZ579852A (OSRAM) |
| PE (1) | PE20090186A1 (OSRAM) |
| PL (1) | PL2124973T3 (OSRAM) |
| PT (1) | PT2124973E (OSRAM) |
| RU (1) | RU2009139002A (OSRAM) |
| TN (1) | TN2009000387A1 (OSRAM) |
| TW (1) | TW200904456A (OSRAM) |
| WO (1) | WO2008116806A1 (OSRAM) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102118478B1 (ko) | 2009-03-09 | 2020-06-04 | 바스프 에이에스 | 지방산 오일 혼합물 및 계면활성제를 포함하는 조성물, 및 이의 방법 및 용도 |
| KR101759255B1 (ko) | 2015-09-18 | 2017-07-18 | 한국산업기술대학교산학협력단 | 무촉매 방식 가변경사각을 갖는 나노 구조물 성장 방법 |
| AR118962A1 (es) * | 2019-05-22 | 2021-11-10 | Bayer Consumer Care Ag | Preparaciones de cápsulas de gelatina blanda de vitaminas y minerales que comprenden vitamina c en forma de una sal de ascorbato |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2043487A1 (OSRAM) * | 1969-05-28 | 1971-02-19 | Commissariat Energie Atomique | |
| US5298237A (en) * | 1992-01-24 | 1994-03-29 | The Trustees Of Columbia University In The City Of New York | Gel composition for reduction of gingival inflammation and retardation of dental plaque |
| US5641512A (en) * | 1995-03-29 | 1997-06-24 | The Procter & Gamble Company | Soft gelatin capsule compositions |
| US20030004043A1 (en) * | 2001-06-27 | 2003-01-02 | Deola James A. | Pivoting backrest for exercise apparatus |
| US20030104043A1 (en) * | 2001-12-03 | 2003-06-05 | Brown Beverly Ann | Topical cream for alleviating spider veins |
| US20050249820A1 (en) * | 2004-05-04 | 2005-11-10 | Akorn, Inc. | Nutritional supplement for the treatment and prevention of macular degeneration |
| US7887847B2 (en) * | 2004-05-08 | 2011-02-15 | Paul Jr Edward L | Nutritional supplement for treatment of ocular diseases |
| CN102908361A (zh) * | 2004-07-09 | 2013-02-06 | 罗伯特·萨宾 | 治疗哺乳动物疾病的组合物及使用方法 |
| US7449196B2 (en) * | 2004-07-09 | 2008-11-11 | Robert Sabin | Anti tumor compositions and methods of use |
| EA010802B1 (ru) * | 2004-11-19 | 2008-12-30 | Мартек Байосайенсиз Корпорейшн | Оксилипины из полиненасыщенных жирных кислот с длинной цепью и способы их получения и применения |
-
2008
- 2008-03-19 JP JP2010500223A patent/JP2010521534A/ja active Pending
- 2008-03-19 EP EP08718009.7A patent/EP2124973B1/en active Active
- 2008-03-19 DK DK08718009.7T patent/DK2124973T3/da active
- 2008-03-19 AU AU2008231847A patent/AU2008231847B2/en active Active
- 2008-03-19 MX MX2009010244A patent/MX2009010244A/es not_active Application Discontinuation
- 2008-03-19 PT PT87180097T patent/PT2124973E/pt unknown
- 2008-03-19 CA CA2681514A patent/CA2681514C/en active Active
- 2008-03-19 WO PCT/EP2008/053283 patent/WO2008116806A1/en not_active Ceased
- 2008-03-19 BR BRPI0809258A patent/BRPI0809258B8/pt active IP Right Grant
- 2008-03-19 KR KR1020097022078A patent/KR101688656B1/ko active Active
- 2008-03-19 MY MYPI20093944A patent/MY164520A/en unknown
- 2008-03-19 NZ NZ579852A patent/NZ579852A/en not_active IP Right Cessation
- 2008-03-19 RU RU2009139002/15A patent/RU2009139002A/ru not_active Application Discontinuation
- 2008-03-19 PL PL08718009T patent/PL2124973T3/pl unknown
- 2008-03-19 PE PE2008000520A patent/PE20090186A1/es not_active Application Discontinuation
- 2008-03-19 AR ARP080101138A patent/AR065791A1/es not_active Application Discontinuation
- 2008-03-19 ES ES08718009.7T patent/ES2542694T3/es active Active
- 2008-03-20 US US12/052,016 patent/US20080233182A1/en not_active Abandoned
- 2008-03-20 CL CL200800804A patent/CL2008000804A1/es unknown
- 2008-03-21 TW TW097110250A patent/TW200904456A/zh unknown
-
2009
- 2009-09-22 GT GT200900251A patent/GT200900251A/es unknown
- 2009-09-22 TN TNP2009000387A patent/TN2009000387A1/fr unknown
- 2009-09-22 IL IL201109A patent/IL201109A/en active IP Right Grant
- 2009-09-23 CO CO09103873A patent/CO6230993A2/es not_active Application Discontinuation
- 2009-10-02 MA MA32248A patent/MA31293B1/fr unknown
- 2009-10-23 EC EC2009009700A patent/ECSP099700A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP099700A (es) | 2009-11-30 |
| US20080233182A1 (en) | 2008-09-25 |
| KR101688656B1 (ko) | 2016-12-21 |
| TN2009000387A1 (en) | 2010-12-31 |
| PT2124973E (pt) | 2015-09-01 |
| KR20100015799A (ko) | 2010-02-12 |
| ES2542694T3 (es) | 2015-08-10 |
| IL201109A (en) | 2016-10-31 |
| PL2124973T3 (pl) | 2015-10-30 |
| DK2124973T3 (da) | 2015-06-22 |
| PE20090186A1 (es) | 2009-03-20 |
| GT200900251A (es) | 2018-10-08 |
| BRPI0809258A2 (pt) | 2014-09-23 |
| MA31293B1 (fr) | 2010-04-01 |
| JP2010521534A (ja) | 2010-06-24 |
| TW200904456A (en) | 2009-02-01 |
| IL201109A0 (en) | 2010-05-17 |
| EP2124973B1 (en) | 2015-05-27 |
| BRPI0809258B8 (pt) | 2021-05-25 |
| EP2124973A1 (en) | 2009-12-02 |
| WO2008116806A1 (en) | 2008-10-02 |
| MX2009010244A (es) | 2009-10-26 |
| CA2681514C (en) | 2016-11-08 |
| MY164520A (en) | 2017-12-29 |
| BRPI0809258B1 (pt) | 2019-10-01 |
| AU2008231847A1 (en) | 2008-10-02 |
| AU2008231847B2 (en) | 2012-12-06 |
| RU2009139002A (ru) | 2011-04-27 |
| NZ579852A (en) | 2012-03-30 |
| CL2008000804A1 (es) | 2008-10-24 |
| CA2681514A1 (en) | 2008-10-02 |
| AR065791A1 (es) | 2009-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pérez-Gálvez et al. | Carotenoids and chlorophylls as antioxidants | |
| Young et al. | Antioxidant and prooxidant properties of carotenoids | |
| Bazan | Homeostatic regulation of photoreceptor cell integrity: Significance of the potent mediator neuroprotectin D1 biosynthesized from docosahexaenoic acid the proctor lecture | |
| DE202011050351U1 (de) | Diätetische Erzeugnisse bzw. Formulierungen | |
| CO6220929A2 (es) | Composicion complementaria para el tratamiento de enfermedades oculares | |
| RU2009126740A (ru) | Композиция питательной добавки, предназначенная для лечения глазных болезней | |
| CO6230993A2 (es) | Uso de una sal de cobre enmascarada o recubierta para el tratamiento de degeneracion macular | |
| US20200261488A1 (en) | Method for treating traumatic brain injury | |
| WO2008024020A1 (fr) | Composition liposomale d'antioxydants pour inhalations en cas de maladies des poumons et des voies respiratoires supérieures | |
| Matsushita et al. | Antioxidant activity of polar carotenoids including astaxanthin-β-glucoside from marine bacterium on PC liposomes | |
| EP1861109A2 (en) | Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of proliferative disorders | |
| RU2181757C2 (ru) | Состав для стабилизации липидов | |
| Perri et al. | Proliferative and anti-proliferative effects of retinoic acid at doses similar to endogenous levels in Leydig MLTC-1/R2C/TM-3 cells | |
| AR070405A1 (es) | Composiciones para la prevencion y/o el tratamiento de la degeneracion macular y/o la perdida de la agudeza visual | |
| JP2008533075A (ja) | ビタミン混合物 | |
| JP2010521534A5 (OSRAM) | ||
| Banik et al. | A critical insight into the physicochemical stability of macular carotenoids with respect to their industrial production, safety profile, targeted tissue delivery, and bioavailability | |
| Chatgilialoglu et al. | Biomimetic chemistry: radical reactions in vesicle suspensions | |
| JOSHI et al. | Docosahexaenoic acid reverses aluminium induced alteration in vitamins and lipid profiles in rat serum | |
| UA144000U (uk) | ПРЕПАРАТ ЛІПОСОМАЛЬНОГО <font face="Symbol">b</font>-КАРОТИНУ ДЛЯ ЛІКУВАННЯ І ПРОФІЛАКТИКИ ГІПОВІТАМІНОЗУ А | |
| EP1974733A1 (en) | Use of a masked or coated copper salt for the treatment of macular degeneration | |
| Sijben et al. | Synaptic membrane synthesis in rats depends on dietary sufficiency of vitamin C, vitamin E, and selenium: Relevance for alzheimer's disease | |
| MX2019015378A (es) | Formulación de vehículo liposomal para liberación controlada de moléculas activas. | |
| UA105383U (uk) | Спосіб контролю за ефективністю лікувальних препаратів при ентеропатології телят |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |